3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
199
Rectal Neoplasms
106
Colonic Neoplasms
78
Stomach Neoplasms
64
Pancreatic Neoplasms
56
Neoplasm Metastasis
50
Esophageal Neoplasms
34
Neoplasms
25
Lymphoma
24
Leukemia
24
Adenocarcinoma Of Esophagus
22
Burkitt Lymphoma
20
Precursor Cell Lymphoblastic Leukemia-Lymphoma
19
Carcinoma, Hepatocellular
16
Cholangiocarcinoma
15
Adenocarcinoma
15
Biliary Tract Neoplasms
12
Gallbladder Neoplasms
9
Bile Duct Neoplasms
8
Lymphoma, Mantle-Cell
7
Colorectal Cancer Metastatic
7
Osteosarcoma
6
Esophageal Squamous Cell Carcinoma
6
Lymphoma, Non-Hodgkin
5
Lymphoma, Large B-Cell, Diffuse
5
Liver Neoplasms
5
Dendritic Cell Sarcoma, Interdigitating
5
Breast Neoplasms
5
Sarcoma
4
Peritoneal Neoplasms
4
Interventions
Cyclophosphamide
3
tumor necrosis factor-alpha, CNGRC fusion protein, human
2
liposomal doxorubicin
2
Paclitaxel
2
Gemcitabine
2
Doxorubicin
2
Dexamethasone
2
Cisplatin
2
Carboplatin
2
Bortezomib
2
vandetanib
1
umbralisib
1
ublituximab
1
regorafenib
1
pomalidomide
1
pembrolizumab
1
nilotinib
1
marizomib
1
lutetium Lu 177 dotatate
1
grapiprant
1
fludarabine phosphate
1
fludarabine
1
durvalumab
1
cemiplimab
1
carotuximab
1
axicabtagene ciloleucel
1
avelumab
1
Thioctic Acid
1
Tamoxifen
1
Receptors, Interleukin-6
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Disease Progression
×
Leucovorin
×
Clear all
NCT05712356
2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2
Terminated
66 enrolled
12 charts